HalcyGen
-
HalcyGen to begin Marketing Authorization Application in Europe
HalcyGen Pharmaceuticals has announced that preliminary results from its UK-based Pharmacokinetic (PK) study comparing a half-dose of anti-fungal drug Suba-Itraconazole with Sporanox, has shown clinical bioequivalence within EU guidelines. Follow…
HalcyGen | 11 March 2010
-
Halcygen to Acquire Subsidiary of Hospira Australia
HalcyGen Pharmaceuticals has entered into an agreement with Hospira Australia, to acquire all the outstanding shares in Mayne Pharma International (MPI) – one of the businesses that Hospira purchased when it acquired Mayne Pharma in 2007 - for US$1…
HalcyGen | 02 October 2009
